250 related articles for article (PubMed ID: 31912677)
21. Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer.
Forsse D; Berg HF; Bozickovic O; Engerud H; Halle MK; Hoivik EA; Woie K; Werner HMJ; Haldorsen IS; Trovik J; Krakstad C
Gynecol Oncol; 2021 Feb; 160(2):396-404. PubMed ID: 33317908
[TBL] [Abstract][Full Text] [Related]
22. Lymphovascular space invasion and the treatment of stage I endometrioid endometrial cancer.
van der Putten LJ; Geels YP; Ezendam NP; van der Putten HW; Snijders MP; van de Poll-Franse LV; Pijnenborg JM
Int J Gynecol Cancer; 2015 Jan; 25(1):75-80. PubMed ID: 25356534
[TBL] [Abstract][Full Text] [Related]
23. [High dose rate vaginal brachytherapy in endometrial cancer after surgery].
Moreau-Claeys MV; Brunaud C; Hoffstetter S; Buchheit I; Peiffert D
Cancer Radiother; 2011 Jun; 15(3):169-75. PubMed ID: 21237693
[TBL] [Abstract][Full Text] [Related]
24. [Long-term oncological outcomes after laparoscopic versus abdominal radical hysterectomy in stage I a2- II a2 cervical cancer: a matched cohort study].
Wang W; Shang C; Huang J; Chen S; Shen H; Yao S
Zhonghua Fu Chan Ke Za Zhi; 2015 Dec; 50(12):894-901. PubMed ID: 26887872
[TBL] [Abstract][Full Text] [Related]
25. Preoperative prognostic factors and effects of adjuvant therapy on outcomes of early stage cervical cancer in Iran.
Behtash N; Karimi Zarchi M; Deldar M
Asian Pac J Cancer Prev; 2009; 10(4):613-8. PubMed ID: 19827880
[TBL] [Abstract][Full Text] [Related]
26. Pelvic lymphadenectomy as alternative to postoperative radiotherapy in high risk early stage endometrial cancer.
Papanikolaou A; Kalogiannidis I; Goutzioulis M; Misailidou D; Makedos A; Vergote I; Makedos G
Arch Gynecol Obstet; 2006 May; 274(2):91-6. PubMed ID: 16518607
[TBL] [Abstract][Full Text] [Related]
27. Embryologically based radical hysterectomy as peritoneal mesometrial resection (PMMR) with pelvic and para-aortic lymphadenectomy for loco-regional tumor control in endometrial cancer: first evidence for efficacy.
Kimmig R; Iannaccone A; Aktas B; Buderath P; Heubner M
Arch Gynecol Obstet; 2016 Jul; 294(1):153-60. PubMed ID: 26596725
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors in FIGO stage IB cervical cancer without lymph node metastasis and the role of adjuvant radiotherapy after radical hysterectomy.
Ayhan A; Al RA; Baykal C; Demirtas E; Ayhan A; Yüce K
Int J Gynecol Cancer; 2004; 14(2):286-92. PubMed ID: 15086728
[TBL] [Abstract][Full Text] [Related]
29. Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial.
Eltabbakh GH; Piver MS; Hempling RE; Shin KH
Int J Radiat Oncol Biol Phys; 1997 May; 38(2):373-80. PubMed ID: 9226326
[TBL] [Abstract][Full Text] [Related]
30. Current therapy of patients with endometrial carcinoma. A critical review.
Marnitz S; Köhler C
Strahlenther Onkol; 2012 Jan; 188(1):12-20. PubMed ID: 22189438
[TBL] [Abstract][Full Text] [Related]
31. Potential benefit of lymphadenectomy for the treatment of node-negative locally advanced uterine cancers.
Seago DP; Raman A; Lele S
Gynecol Oncol; 2001 Nov; 83(2):282-5. PubMed ID: 11606085
[TBL] [Abstract][Full Text] [Related]
32. Is the risk of substantial LVSI in stage I endometrial cancer similar to PORTEC in the North American population? - A single-institution study.
Pifer PM; Bhargava R; Patel AK; Ling DC; Vargo JA; Orr BC; Sukumvanich P; Courtney-Brooks MB; Boisen MM; Berger JL; Taylor S; Olawaiye AB; Comerci JT; Lesnock JL; Edwards RP; Beriwal S
Gynecol Oncol; 2020 Oct; 159(1):23-29. PubMed ID: 32718729
[TBL] [Abstract][Full Text] [Related]
33. Postoperative nomogram for the prediction of disease-free survival in lymph node-negative stage I-IIA cervical cancer patients treated with radical hysterectomy.
Gülseren V; Kocaer M; Çakır İ; Özdemir İA; Sancı M; Güngördük K
J Obstet Gynaecol; 2020 Jul; 40(5):699-704. PubMed ID: 31607197
[TBL] [Abstract][Full Text] [Related]
34. The nature of early-stage endometrial cancer recurrence-A national cohort study.
Jeppesen MM; Jensen PT; Gilså Hansen D; Iachina M; Mogensen O
Eur J Cancer; 2016 Dec; 69():51-60. PubMed ID: 27816832
[TBL] [Abstract][Full Text] [Related]
35. Influence of body mass index on clinicopathologic features, surgical morbidity and outcome in patients with endometrial cancer.
Akbayır O; Corbacıoglu Esmer A; Numanoglu C; Cılesız Goksedef BP; Akca A; Bakır LV; Kuru O
Arch Gynecol Obstet; 2012 Nov; 286(5):1269-76. PubMed ID: 22729137
[TBL] [Abstract][Full Text] [Related]
36. Sentinel lymph node mapping with staging lymphadenectomy for patients with endometrial cancer increases the detection of metastasis.
Holloway RW; Gupta S; Stavitzski NM; Zhu X; Takimoto EL; Gubbi A; Bigsby GE; Brudie LA; Kendrick JE; Ahmad S
Gynecol Oncol; 2016 May; 141(2):206-210. PubMed ID: 26905211
[TBL] [Abstract][Full Text] [Related]
37. Does ovarian preservation have an effect on recurrence of early stage low-grade endometrial stromal sarcoma?
Karataşlı V; Çakır İ; Can B; Erkılınç S; Karadeniz T; Kuru O; Gökçü M; Sancı M
J Obstet Gynaecol; 2021 Jul; 41(5):797-802. PubMed ID: 33063586
[TBL] [Abstract][Full Text] [Related]
38. Call for Surgical Nodal Staging in Women with ESMO/ESGO/ESTRO High-Intermediate Risk Endometrial Cancer: A Multicentre Cohort Analysis from the FRANCOGYN Study Group.
Ouldamer L; Bendifallah S; Body G; Canlorbe G; Touboul C; Graesslin O; Raimond E; Collinet P; Coutant C; Lavoué V; Lévêque J; Daraï E; Ballester M;
Ann Surg Oncol; 2017 Jun; 24(6):1660-1666. PubMed ID: 28058558
[TBL] [Abstract][Full Text] [Related]
39. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
[TBL] [Abstract][Full Text] [Related]
40. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.
Bosse T; Peters EE; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Mens JW; Lutgens LC; van der Steen-Banasik EM; Smit VT; Nout RA
Eur J Cancer; 2015 Sep; 51(13):1742-50. PubMed ID: 26049688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
